- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07607691
Ultrasound-Guided PENG Block for Chronic Shoulder Pain
Evaluation of the Analgesic Efficacy and Functional Outcomes of Ultrasound-Guided PENG Block in Chronic Shoulder Pain
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Study Design and Setting:
This is a prospective, observational, and single-center clinical study designed to evaluate the clinical and functional outcomes of ultrasound-guided Pericapsular Nerve Group (PENG) block in patients with chronic shoulder pain. The study will be conducted in accordance with the Declaration of Helsinki, and approval from the local clinical research ethics committee will be obtained prior to patient enrollment.
Patient Selection:
Adult patients (aged over 18 years) presenting with chronic shoulder pain lasting longer than 3 months, who have an initial Numerical Rating Scale (NRS) score greater than 4 and have not responded to conservative or medical treatments, will be screened for eligibility. Written informed consent will be obtained from all participating individuals. Patients with coagulation disorders, psychomotor disorders, active infections at the injection site, a history of shoulder surgery within the past 6 months, or known allergies to local anesthetics or corticosteroids will be excluded.
Intervention Protocol:
The ultrasound-guided shoulder PENG block is performed as a routine treatment modality in our clinic for patients non-responsive to conservative therapies. The procedure is conducted under sterile conditions with the patient in the supine position. The affected shoulder is placed in abduction and external rotation. An ultrasound transducer is positioned parallel to the clavicle to visualize the anatomical structures. A block needle is advanced under the subscapularis muscle under direct ultrasound guidance. Following the confirmation of correct needle positioning, a mixture of 5 mL of 2% lidocaine and 8 mg of dexamethasone is injected into the periarticular nerve endpoints. Outcome Measurements and Data Collection:
Demographic and clinical data will be collected by an expert algologist using the hospital information management system and recorded into dedicated study forms. Clinical parameters will be evaluated at four distinct time points: baseline (pre-procedure), 1st week, 4th week (1 month), and 3rd month post-procedure. Pain severity will be measured using the Numerical Rating Scale (NRS). Shoulder joint function and disability levels will be assessed using the Shoulder Pain and Disability Index (SPADI). Overall patient satisfaction and perceived improvement will be tracked via the Global Perceived Effect (GPE) scale.
Friedman test, depending on the distribution properties. Bonferroni correction will be applied for post-hoc pairwise comparisons, and a p-value less than 0.05 will be considered statistically significant.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: ali çoştu, md
- Telefonní číslo: +905427669038
- E-mail: alicostu@gmail.com
Studijní záloha kontaktů
- Jméno: Tolga kaplan, md
- Telefonní číslo: +905304069410
- E-mail: tolgakaplan1994@gmail.com
Studijní místa
-
-
çankaya
-
Ankara, çankaya, Turecko (Türkiye), 06810
- Ankara Bilkent City Hospital
-
Kontakt:
- ali çoştu, md
- Telefonní číslo: +905427669038
- E-mail: alicostu@gmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Age 18 years or older.
- Patients presenting with chronic shoulder pain lasting longer than 3 months.
- Initial pain intensity score greater than 4 on the Numerical Rating Scale (NRS > 4).
- Patients who have not responded to conservative or medical treatments.
- Voluntary acceptance of the ultrasound-guided shoulder PENG block treatment and compliance with the scheduled follow-up protocol.
Exclusion Criteria:
- Patients currently using anticoagulants or diagnosed with coagulation disorders (bleeding diathesis).
- Patients with psychomotor or cognitive disorders that prevent cooperative evaluation.
- Presence of active bacterial infection, open wounds, or infectious discharge at the planned needle injection site.
- History of shoulder surgery at the intervention site within the last 6 months.
- Known allergy or hypersensitivity to local anesthetics (lidocaine) or corticosteroids (dexamethasone).
- Pregnant or breastfeeding patients.
- Patients who reject the procedure or fail to comply with the scheduled follow-up visits.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: PENG Block Group
Patients with chronic shoulder pain who receive an ultrasound-guided Pericapsular Nerve Group (PENG) block.
Under sterile conditions and in the supine position, with the shoulder in abduction and external rotation, an ultrasound transducer is placed parallel to the clavicle.
A block needle is advanced under the subscapularis muscle.
Following confirmation of the needle position, a mixture of 5 mL of 2% lidocaine and 8 mg of dexamethasone is administered to the periarticular nerve endpoints.
|
An ultrasound-guided Pericapsular Nerve Group (PENG) block is administered to target the articular (sensory) branches of the nerves innervating the shoulder joint capsule (suprascapular, axillary, and lateral pectoral nerves) without affecting the motor branches. The intervention is performed under strict sterile conditions with the patient in the supine position. The affected shoulder is placed in abduction and external rotation. A high-frequency ultrasound transducer is positioned parallel to the clavicle to visualize the anatomical structures. Under direct ultrasound guidance, a block needle is advanced beneath the subscapularis muscle. After confirming the correct needle positioning and ensuring no intravascular placement, a therapeutic mixture of 5 mL of 2% lidocaine and 8 mg of dexamethasone is injected into the periarticular nerve endpoints. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from Baseline Numerical Rating Scale (NRS) Score
Časové okno: Baseline (pre-procedure), post-procedure 30th minute, 1st week, 4th week (1st month), and 12th week (3rd month)
|
The Numerical Rating Scale (NRS) is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain.
The score ranges from 0 to 10, where 0 indicates "no pain" and 10 indicates "the worst possible pain."
Higher scores represent more severe pain intensity.
Pain levels will be evaluated and compared across different time points
|
Baseline (pre-procedure), post-procedure 30th minute, 1st week, 4th week (1st month), and 12th week (3rd month)
|
|
Change from Baseline Shoulder Pain and Disability Index (SPADI) Score
Časové okno: Baseline (pre-procedure), 1st week, 4th week (1st month), and 12th week (3rd month)
|
The Shoulder Pain and Disability Index (SPADI) is a self-administered questionnaire used to measure shoulder pain and disability.
It consists of 13 items divided into two subscales: pain (5 items) and disability (8 items).
Each item is scored on a visual analog scale ranging from 0 (no pain/no difficulty) to 10 (worst pain imaginable/so difficult it requires help).
The total SPADI score is calculated by averaging the subscale scores and ranges from 0 to 100, where 0 indicates the best possible shoulder function (no pain and disability) and 100 indicates the worst possible shoulder function (severe pain and disability).
Higher scores represent greater pain and disability
|
Baseline (pre-procedure), 1st week, 4th week (1st month), and 12th week (3rd month)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Global Perceived Effect (GPE) Score
Časové okno: Post-procedure 1st week, 4th week (1st month), and 12th week (3rd month).
|
The Global Perceived Effect (GPE) scale is a patient-reported outcome measure used to assess the patient's subjective perception of recovery or improvement since the beginning of the treatment.
It is scored on a Likert-type scale (typically ranging from 1 to 7 or -5 to +5, with specific anchor points).
For this study, a standard 7-point Likert scale will be used, where 1 indicates "extremely worsened", 4 indicates "no change", and 7 indicates "extremely improved".
Higher scores represent a higher level of patient satisfaction and perceived clinical improvement.
|
Post-procedure 1st week, 4th week (1st month), and 12th week (3rd month).
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: ali çoştu, md, Ankara City Hospital Bilkent
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Bolest
- Neurologické projevy
- Nemoci pohybového aparátu
- Onemocnění kloubů
- Artralgie
- Patologické stavy, příznaky a symptomy
- Příznaky a symptomy
- Bursitida
- Bolest ramene
- Organické chemikálie
- Polycyklické sloučeniny
- Anilides
- Amidy
- Anilinové sloučeniny
- Aminy
- Acetanilidy
- Těhotenství
- Těhotenství
- Steroidy
- Sloučeniny roztaveného kruhu
- Steroidy, fluorované
- Těhotenství
- Dexamethason
- Lidokain
Další identifikační čísla studie
- E2-26-14592
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Lidocaine and Dexamethasone for PENG Block
-
Weill Medical College of Cornell UniversityNew York Presbyterian HospitalNábor